Prescribing information (package insert) - Sunharbo
1 INDICATIONS AND USAGE
Sunharbo is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk transient ischemic attack (TIA).
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
The recommended dosage of Sunharbo is 50 mg orally once daily. Tablets may be taken with or without food.
2.2 Preparation and Administration
Swallow SUNHARBO tablets whole.
For patients who are unable to swallow whole tablets, the Sunharbo tablet may be administered in the following ways:
Oral Administration of Crushed Tablets
- Crush the tablet (a tablet crusher is recommended).
- Mix the crushed tablet with water or soft foods.
- Consume the entire mixture immediately.
Feeding Tube Administration (nasogastric or gastric tube)
- Place an intact tablet in a syringe with 10 mL of non-carbonated water and shake for 15 seconds every 30 minutes for 2 hours. Shake for at least 15 seconds immediately before administration.
- Alternatively, crush the tablet (a tablet crusher is recommended), suspend in 10 mL of non-carbonated water, and transfer the suspension to a syringe.
- Administer the entire suspension according to feeding tube instructions.
- After administration, rinse all preparation equipment twice with a total of 10 mL of non-carbonated water flushes each time. Administer each rinse via the feeding tube.
Storage of the Prepared Syringe
If needed, the resulting suspension can be stored in the syringe between 2°C to 30°C (36°F to 86°F) for up to 24 hours. Label the syringe with the product name (Sunharbo), the dose strength (50 mg), and the time/date of preparation. Immediately before administration, shake the syringe again for about 15 seconds.
2.3 Missed Dose
Patients should take a missed dose as soon as possible on the same day. If the missed dose cannot be taken within the same day, the patient should skip the missed dose and resume with the next scheduled dose at the regular time.
2.4 Patients Undergoing Surgery and Other Invasive Procedures
Sunharbo should be interrupted at least 24 hours before elective surgery or invasive procedure. Sunharbo should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.
2.5 Patients Undergoing Thrombolysis
Thrombolysis (with or without thrombectomy): Concomitant use of Sunharbo within 48 hours prior to thrombolysis has not been studied and the risk of bleeding is unknown. Sunharbo should be withheld for at least 24 hours after thrombolysis for acute ischemic stroke.
3 DOSAGE FORMS AND STRENGTHS
Film-coated tablet: 50 mg, oval, biconvex, dark orange, marked 'BAY' on one side and '50' on the other side.
4 CONTRAINDICATIONS
None.
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of Sunharbo was evaluated in adults after a non-cardioembolic ischemic stroke or high-risk TIA in the OCEANIC-STROKE study, in which 6,124 patients received Sunharbo 50 mg once daily and 6,130 patients received placebo over a median duration of 14.2 months. [see Clinical Studies (14)].
In the OCEANIC-STROKE study, 67% of the patients received dual antiplatelet therapy (DAPT) (median duration 32 days) and 87% of the patients received single antiplatelet therapy (SAPT) (median duration 498 days). As patients may have switched antiplatelet therapy during the study, they may be included in more than one category.
Among treated patients, approximately 30% received a prophylactic dose of heparins including low molecular weight heparins (LMWH) and heparinoids (median duration 4 days) concomitantly within the intervention period.
Bleeding
The primary safety endpoint in the OCEANIC-STROKE study was International Society on Thrombosis and Haemostasis (ISTH) major bleeding. The rate of ISTH major bleeding was similar between Sunharbo and placebo groups (1.6 vs. 1.5 per 100 person-years) with a hazard ratio (HR) of 1.1 (95% CI: 0.8-1.4) in a time-to-event analysis using the Cox proportional hazards model and log-rank test. The rate of ISTH major bleeding events within 90 days of treatment initiation was 4.5 vs. 3.1 per 100 person-years in the Sunharbo and placebo groups, respectively (HR: 1.46 [95% CI: 0.99, 2.16]).
In patients planned to receive DAPT, the rate of ISTH major bleeding events was 1.9 vs. 1.5 per 100 person-years in the Sunharbo and placebo groups, respectively. In subjects not planned to receive DAPT, rates were similar between groups (1.3 vs. 1.4 per 100 person-years).
Among patients older than 75 years (25% of the study population), the rate of ISTH major bleeding was 2.6 vs. 1.7 per 100 person-years in the Sunharbo and placebo groups, respectively.
In the high-risk TIA subgroup (5% of the study population), the rate of ISTH major bleeding was 2.9 vs. 1.0 per 100 person-years in the Sunharbo and placebo groups, respectively; the median onset of ISTH major bleeding events in the high-risk TIA subgroup receiving Sunharbo was 30 days.
Table 1 summarizes the results of the bleeding endpoints in the OCEANIC-STROKE study. The rate of gastrointestinal (GI) bleeding was higher in the Sunharbo compared to placebo group (2.7 vs. 2.1 per 100 patient-years) with a HR of 1.3 (95% CI: 1.0, 1.6). The majority of GI bleeding events in the Sunharbo group (74%) were clinically relevant non-major or minor bleeding, and the most frequent bleeding site was of rectal origin.
Table 1: Bleeding Endpoints in the OCEANIC-STROKE Study
Sunharbo N=6124 | Placebo N=6130 | ||
|---|---|---|---|
| n (n per 100 patient-years) | n (n per 100 patient-years) | Hazard Ratio (95% CI) | |
| Abbreviations: N = number of subjects, n = number of subjects with event; rate calculated per 100 patient-years exposure, CI = confidence interval, ISTH = International Society on Thrombosis and Haemostasis | |||
| ISTH major bleeding: Fatal bleeding, and/or symptomatic bleeding in a critical site, and/or clinically overt bleeding with hemoglobin drop ≥ 2 g/dL or requiring transfusion of ≥ 2 units of red blood cells | |||
| ISTH clinically relevant non-major bleeding: Clinically overt bleeding meeting at least one of the following criteria: requiring treatment by a healthcare professional, leading to hospitalization or increased level of care, requiring change in antithrombotic therapy, and is not ISTH major bleeding | |||
| Minor bleeding: All other overt bleeding that does not meet the above criteria for ISTH major or clinically relevant non-major bleeding | |||
| ISTH major bleedingTime to first occurrence | 117 (1.6) | 107 (1.5) | 1.1 (0.8, 1.4) |
| Composite of ISTH major or clinically relevant non-major bleeding | 339 (4.9) | 307 (4.4) | 1.1 (1.0, 1.3) |
| ISTH clinically relevant non-major bleeding | 231 (3.3) | 210 (3.0) | 1.1 (0.9, 1.3) |
| Symptomatic intracranial hemorrhage | 41 (0.6) | 36 (0.5) | 1.2 (0.7, 1.8) |
| Hemorrhagic stroke | 13 (0.2) | 20 (0.3) | 0.7 (0.3, 1.3) |
| Fatal bleeding | 14 (0.2) | 8 (0.1) | 1.8 (0.7, 4.2) |
| Minor bleeding | 479 (7.2) | 512 (7.6) | 0.9 (0.8, 1.1) |
| Gastrointestinal bleeding | 186 (2.7) | 147 (2.1) | 1.3 (1.0, 1.6) |
In the OCEANIC-STROKE study, the incidence of adverse events leading to treatment discontinuation was similar between Sunharbo and placebo groups (10% in each group). The most common reason for treatment discontinuation in both groups was newly diagnosed atrial fibrillation (~5% in each group), for which permanent discontinuation of Sunharbo was required.
The most frequently reported (>3%) adverse reaction in Sunharbo-treated patients was diarrhea (3.4% vs. 2.8% in the Sunharbo and placebo groups, respectively). Most cases of diarrhea in Sunharbo-treated patients were reported within the first two months of treatment, were mild in severity, and resolved while on Sunharbo (77%).
Hepatic enzyme increased
Clinical data indicate that Sunharbo is associated with elevated hepatic enzymes. In the OCEANIC-STROKE study, an elevation of alkaline phosphatase (ALP) more than 2 times above the upper limit of the normal range was observed in 2.0% versus 1.8% in the Sunharbo and placebo groups, respectively. Elevation of serum transaminases more than 3 times above the upper limit of the normal range without a simultaneous elevation in total bilirubin was observed in 2.0% of Sunharbo-treated patients and 1.6% of placebo-treated patients. The majority (74%) of the hepatic enzyme increased events in Sunharbo-treated patients were reported as mild in severity. Substantial cholestatic liver injury (ALP >1000 U/L) or serious liver injury with jaundice were each reported in less than 0.02% of Sunharbo-treated patients, with the greatest risk observed within the first 6 to 12 months of treatment with Sunharbo.
7 DRUG INTERACTIONS
7.1 Effect of Sunharbo on Other Drugs
P-gp substrates
Asundexian inhibits the P-gp transporter. Concomitant use of asundexian increased the exposure to digoxin [see Clinical Pharmacology (12.3)].
Follow the recommendation in the approved product labeling for digoxin and sensitive P-gp substrates where minimal concentration changes may increase the risk of adverse reactions.
7.2 Effect of Other Drugs on Sunharbo
Asundexian is cleared via carboxylesterase 1 (CES1) and to a minor extent via cytochrome P450 isoform 3A4 (CYP3A4). Asundexian is a substrate for the P‑glycoprotein (P-gp).
Combined P-gp and strong CYP3A4 inducers
Avoid concomitant use with combined P-gp and strong CYP3A4 inducers, which decreases asundexian exposure and may lead to loss of efficacy [see Clinical Pharmacology (12.3)].
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
There are no available data on Sunharbo use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother associated with untreated non-cardioembolic ischemic stroke or TIA and risk of bleeding in the mother and fetus or neonate associated with use of anticoagulants during pregnancy (see Clinical Considerations).
In animal reproduction studies, no treatment-related malformations were observed in rats and rabbits at asundexian exposures approximately up to 15 times and 3 times, respectively, the clinical exposure at the recommended human dose (RHD), based on area under the concentration-time curve (AUC). In rats, embryo-fetal effects (increased incidence of stillborn or dead pups and lower pup weights) were observed at asundexian exposures approximately 9 times the clinical exposure (AUC) at the RHD (see Data ).
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Pregnant women exposed to Sunharbo, or their healthcare providers, should report Sunharbo exposure by calling 1-888-842-2937.
Clinical Considerations
Disease-Associated Maternal and/or Embryo/Fetal Risk
Untreated non-cardioembolic ischemic stroke or TIA is associated with adverse maternal outcomes, including maternal death, miscarriage, HELLP syndrome and preterm delivery, and adverse fetal outcomes, including fetal death.
Fetal/Neonatal adverse reactions
Use of anticoagulants, including Sunharbo, may increase the risk of bleeding in the fetus and neonate. Monitor neonates for bleeding.
Labor or delivery
All patients receiving anticoagulants, including pregnant women, are at risk for bleeding. Sunharbo use during labor or delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. Consider use of a shorter acting anticoagulant as delivery approaches.
Data
Animal Data
In pregnant rats, daily oral administration of asundexian (0, 50, 125, 210 mg/kg/day) throughout organogenesis from gestation day (GD) 6 to 17 resulted in embryo-fetal effects (no live fetuses in two females) at 210 mg/kg/day, approximately 15-times the clinical exposure (AUC) at the RHD, which also produced maternal toxicity (reduced body weight gain). No adverse embryo-fetal development effects were observed at doses up to 125 mg/kg/day, approximately 9-times the clinical exposure (AUC) at the RHD. No embryo-fetal malformations were observed at doses up to 210 mg/kg/day in rats, approximately 15-times the clinical exposure at the RHD.
In pregnant rabbits, daily oral administration of asundexian (0, 10, 30, and 110 mg/kg/day) throughout organogenesis from GD 6 to 19 did not result in fetal malformations at doses up to 110 mg/kg/day, approximately 3 times the clinical exposure (AUC) at the RHD.
In a pre- and post-natal development study in rats, daily oral administration of asundexian (0, 50, 125, or 200 mg/kg) throughout pregnancy and lactation (GD 6 to lactation day 21) resulted in embryo-fetal effects (high incidences of stillborn or dead pups, lower pup weight) at 200 mg/kg/day, approximately 9 times the clinical exposure (AUC) at the RHD. No adverse effects on pre- and post-natal development were observed at doses up to 125 mg/kg/day, approximately 8 times the clinical exposure at the RHD, based on AUC.
Following a single administration of radiolabeled asundexian to pregnant rats, asundexian crossed the placenta and was detected in fetuses.
8.2 Lactation
Risk Summary
There are no data on the presence of asundexian or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Animal studies indicate that asundexian was present in the milk of lactating rats (see Data ). When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the potential for serious adverse reactions in nursing infants, including bleeding, advise patients that breastfeeding is not recommended during treatment with Sunharbo and for 5 days after the last dose.
Data
Following a single administration of radiolabeled asundexian to lactating rats, asundexian was detected in milk.
8.4 Pediatric Use
The safety and effectiveness of Sunharbo have not been established in pediatric patients.
8.5 Geriatric Use
Of the 6,162 patients randomized to Sunharbo in the OCEANIC-STROKE study, 62.5% of patients were 65 years and older, and 24.8% were 75 years and older. No overall differences in efficacy were observed between these patients and younger patients. Among patients older than 75 years, the rate of ISTH major bleeding was 2.6 vs. 1.7 per 100 person-years in the Sunharbo and placebo groups, respectively [see Adverse Reactions (6.1)].
8.6 Hepatic Impairment
No dose adjustment is required for patients with mild hepatic impairment (Child-Pugh A) [see Clinical Pharmacology (12.3)].
No data on safety and efficacy are available for patients with moderate to severe hepatic impairment (Child-Pugh B and C). These patients may have intrinsic coagulation abnormalities.
Use of Sunharbo in patients with moderate to severe hepatic impairment (Child-Pugh B and C) is not recommended.
10 OVERDOSAGE
There is no specific therapy for a Sunharbo overdose. In case of overdose the individual should be closely monitored, and supportive treatment should be considered based on signs and symptoms. Due to the high plasma protein binding, asundexian is not dialyzable.
11 DESCRIPTION
Sunharbo (asundexian) is a coated tablet for oral administration. Asundexian is a factor XIa inhibitor and its chemical name is (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32 H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide. The molecular formula is C26H21ClF4N6O4 and the molecular weight is 592.9 g/mol.
The structural formula of asundexian is:

Asundexian is a white to yellowish powder. It is practically insoluble in water and 0.1 M HCl, and soluble in ethanol, acetonitrile, and acetone. The solid asundexian substance is insensitive to thermal stress up to 60°C, non-hygroscopic, and slightly sensitive to light.
Each Sunharbo tablet contains 50 mg asundexian. The inactive ingredients in Sunharbo are croscarmellose sodium, magnesium stearate, and povidone. The film coating contains ferric oxide red, ferric oxide yellow, hypromellose, and polyethylene glycol 3350.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Asundexian is an inhibitor of activated factor XI (FXIa). FXIa leads to downstream activation of Factor X, resulting in thrombin generation via the intrinsic pathway. Thrombin activates Factor XI via a positive feedback loop, which leads to an amplification of thrombus formation and stability. FXIa inhibition reduces amplification of thrombin generation.
12.2 Pharmacodynamics
At the recommended therapeutic dose, asundexian inhibits FXIa activity (by 97% at peak concentrations and by 93% at trough concentrations) and prolongs activated partial thromboplastin time (aPTT) in a concentration-dependent manner.
Kaolin was used to measure aPTT in the Sunharbo clinical studies; other reagents may yield different results.
In clinical pharmacology studies, no changes were observed, at clinically relevant exposures, in prothrombin time (PT) or International Normalized Ratio (INR) values, which assess the tissue factor and common coagulation pathways involving factors I (fibrinogen), II (prothrombin), V, VII, and X.
Routine monitoring of aPTT or other coagulation parameters when treating patients with Sunharbo is not recommended.
Cardiac Electrophysiology
Clinically significant QTc prolongation was not observed at mean plasma concentrations 1.5 times the mean of peak concentration provided by the recommended therapeutic dose.
12.3 Pharmacokinetics
Asundexian maximum concentration (Cmax) is 1430 (Standard Deviation [SD] 370) mcg/L, and total systemic exposure (AUC0-tau) is 25,300 (SD 7600) (hrs*mcg/L) following daily oral dosing of 50 mg in patients with noncardioembolic stroke or high-risk TIA. Asundexian exposure increases dose proportionally following multiple once daily doses of 25 mg to 100 mg. Asundexian accumulation is approximately 1.5-fold at the 50 mg once daily dose. Steady-state exposure to asundexian is reached in approximately 3-5 days.
Absorption
The absolute bioavailability of asundexian is 94%. Asundexian median (min, max) time to maximum plasma concentration (Tmax) is 3 hours (0.75, 6 hours) at steady state. No clinically significant difference in asundexian exposure was observed following administration of either the crushed tablet or whole tablet at the 50 mg dose.
No clinically significant differences in pharmacokinetics of asundexian were observed following administration of a high-fat, high-calorie meal (approximately 800 to 1000 calories with 150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively).
Distribution
Asundexian steady state apparent volume of distribution (Vss/F) is 79 L. Asundexian plasma protein binding is 94% (albumin and/or low-density lipoprotein) and is not concentration dependent, in vitro.
Elimination
The estimated elimination half-life (t1/2) of asundexian is about 24 hours with an apparent (oral) clearance of 2.2 L/hr.
Metabolism
Asundexian is primarily metabolized by CES1 and to a lesser extent by CYP3A4.
Excretion
After a single dose of radiolabeled asundexian 25 mg to healthy subjects, approximately 80% of the administered dose was excreted via feces (28% of the dose unchanged), and approximately 20% was eliminated via urine (9% unchanged). Asundexian is a substrate of P-gp.
Specific Populations
No clinically significant differences in the pharmacokinetics of asundexian were observed based on age (21 to 98 years), sex (67% male and 33% female), race (71% White, 1.4% Black, 0.5% American Indian or Alaska Native, and 26% Asian), renal function (mild, moderate, or severe renal impairment or kidney failure on dialysis, eGFR estimated by CKD-EPI equation) or mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) hepatic impairment. The effect of severe (Child-Pugh Class C) hepatic impairment on asundexian pharmacokinetics is unknown.
Drug Interaction Studies
Clinical Studies and Model-Informed Approaches
Combined P-gp and strong CYP3A4 inhibitors: Asundexian AUC increased by 103% following concomitant administration of itraconazole 200 mg once daily for 7 days. There was no change in the mean Cmax. Limited safety data are available for patients receiving Sunharbo with concomitant medications that are combined P-gp and strong CYP3A4 inhibitors.
Combined P-gp and moderate CYP3A4 inhibitors: Asundexian AUC increased by 76% following concomitant administration with verapamil (240 mg once daily). There was no change in the mean Cmax. Based on clinical data the effect on AUC is considered not clinically relevant.
Combined P-gp and strong CYP3A4 inducers: Asundexian AUC decreased by approximately 44% following concomitant administration of carbamazepine 300 mg twice daily for 18 days. There was no change in the mean Cmax.
P-gp Substrates: Multiple doses of asundexian (75 mg once daily) increased the AUC and Cmax of digoxin (sensitive P-gp substrate) by 40% and 57%, respectively.
CYP2C8 Substrates: Multiple doses of asundexian (75 mg once daily) increased the AUC and Cmax of repaglinide (sensitive CYP2C8 substrate) by 38% and 40%, respectively.
BCRP Substrates: Multiple doses of asundexian (75 mg once daily) increased the AUC and Cmax of rosuvastatin (sensitive BCRP substrate) by 33% and 41%, respectively.
Other drugs
No clinically significant differences in asundexian pharmacokinetics were observed when used concomitantly with fluconazole (moderate CYP3A4 inhibitor), omeprazole (proton pump inhibitor), or an antacid.
No clinically significant differences in the pharmacokinetics of the following drugs were observed when used concomitantly with Sunharbo: oral midazolam (CYP3A4 substrate), atorvastatin, pravastatin (OATP1B1/1B3 substrate) or metformin (MATE1/2K substrate).
In Vitro Studies
CYP Enzymes: Asundexian did not inhibit CYP1A1, 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, or 2J2, or induce CYP1A2, 2B6, or 2C19 at clinically relevant concentrations. Asundexian is an inhibitor of CYP3A4 and CYP2C8 and an inducer of CYP3A4.
Transporter Systems: Asundexian is a substrate of P-gp but not for BCRP, MRP2, MATE1, OATP1B1, or OATP1B3. Asundexian inhibited BSEP, P-gp, BCRP, MATE1/MATE2K, OATP1B1 and OATP1B3 in vitro but did not inhibit MRP2, OAT1, OAT3, OCT1, or OCT2.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
Asundexian did not show carcinogenic potential in a 6-month study in transgenic mice at doses up to 100 mg/kg/day. In a 2-year rat carcinogenicity study, an increased incidence of pancreatic acinar cell adenomas was observed in male rats at all asundexian doses (6, 20 and 60 mg/kg/day); the exposure at low dose is below clinical exposure (AUC) at the RHD. In female rats, the incidence of combined acinar cell adenomas and adenocarcinomas increased at the high dose (90 mg/kg/day), approximately 16-times the clinical exposure (AUC) at the RHD. The clinical relevance of these tumor findings is unclear.
Mutagenesis
Asundexian was negative in a bacterial reverse mutation assay and positive in an in vitro micronucleus (MN) test in Chinese hamster V79 cells. Asundexian was negative in the rat in vivo MN and liver Comet assays. Overall, asundexian was determined to be negative for genotoxicity.
Impairment of Fertility
Asundexian had no effects on male or female fertility in rats administered the drug orally for 2 or 4 weeks prior to mating and throughout the mating period at doses up to 75 mg/kg/day, approximately 7 times the clinical exposure (AUC) at the RHD.
14 CLINICAL STUDIES
The OCEANIC-STROKE study (NCT05686070) was a multicenter, randomized, double-blind, placebo-controlled, and event-driven phase 3 study. The study was designed to demonstrate the efficacy and safety of Sunharbo (50 mg once daily) in combination with antiplatelet therapy for the prevention of ischemic stroke in adults 18 years or older after an index event of acute non-cardioembolic ischemic stroke (National Institutes of Health [NIH] Stroke Scale ≤15) or high-risk TIA (Age, Blood Pressure, Clinical Features, Duration, and Diabetes [ABCD2] score ≥6). Patients were randomized within 72 hours after onset of symptoms.
In addition to the index event, patients should have met at least one of the following criteria: (1) acute non-lacunar infarct on brain imaging, (2) evidence of cerebrovascular atherosclerosis on imaging, or (3) history of coronary, carotid, aortic or peripheral atherosclerotic cardiovascular disease. Patients without evidence of a brain infarct on imaging were required to have at least one of the following signs or symptoms of an acute ischemic stroke/TIA: motor deficit, speech deficit, visual deficit and/or neglect.
Patients were required to undergo brain imaging ruling out hemorrhagic stroke or another etiology for symptoms such as a brain tumor or abscess prior to randomization. Other exclusion criteria included an ischemic stroke within 7 days prior to the index event, an index event related to a procedure or other cause such as bacterial endocarditis, sustained uncontrolled hypertension, active non-trivial bleeding, major surgery during the last 30 days prior to randomization, modified Rankin score ≥ 4 prior to the index event, history of atrial fibrillation/flutter, left ventricular thrombus, mechanical valve, or other cardioembolic source of stroke requiring anticoagulation. Prophylactic doses of anticoagulation were permitted.
The study randomized 12,327 patients to receive either Sunharbo (N=6,162) or placebo (N=6,165), with a median treatment duration of 14.2 months. At randomization, 95% had a documented ischemic stroke and 5% had a high-risk TIA and about 63% of patients were expected to receive DAPT. The median NIH Stroke Scale was 2; NIH Stroke Scale was ≤3, 4-7, and ≥8-15 in 71%, 23%, and 6% of the patients, respectively. The study population was 66% White, 28% Asian, 2% Black, and 3% Other. The mean age at enrollment was 68 years, and 67% of the patients were male and 33% were female. At baseline, 35% had diabetes, 80% hypertension, 16% coronary artery disease, 4% peripheral artery disease, 6% chronic kidney disease and 22% history of stroke or TIA prior to the index event. For treatment of the index stroke, 19% of patients underwent thrombolysis only, 3% underwent thrombectomy only, and 4% had both.
The primary efficacy endpoint was the time to first occurrence of ischemic stroke. The secondary efficacy endpoints were all strokes (ischemic or hemorrhagic); a composite of cardiovascular death, myocardial infarction or stroke; and a composite of all-cause mortality, myocardial infarction, or stroke.
Sunharbo reduced the risk of the primary endpoint of ischemic stroke compared to placebo in a time-to-event analysis using the Cox proportional hazards model and log-rank test: Hazard Ratio (HR) 0.74 (95% CI 0.65-0.84, p<0.0001). See Table 2 and Figure 1. The treatment effect for the primary endpoint was consistent across all predefined subgroups including sex, age, type of index event, stroke severity, DAPT, thrombolysis and/or endovascular therapy.
Sunharbo reduced the risk of secondary endpoints of all strokes (ischemic or hemorrhagic) (HR 0.74, 95% CI 0.65-0.84), the composite of cardiovascular death, myocardial infarction or stroke (HR 0.83, 95% CI 0.74-0.92), and the composite of all-cause mortality, myocardial infarction or stroke (HR 0.86, 95% CI 0.77-0.95) compared to placebo. The results of these secondary endpoints were primarily driven by reduction in ischemic stroke, and there was no difference for all cause-mortality (Table 2).
Figure 1: Time to first occurrence of ischemic stroke in the OCEANIC-STROKE study

Table 2: Primary and secondary efficacy outcomes in the OCEANIC-STROKE study
Sunharbo 50 mg once daily N=6162 | Placebo N=6165 | Treatment Effect Sunharbo / Placebo | ||
|---|---|---|---|---|
| Primary Endpoints: | n (%) | n (%) | Hazard Ratio (95% CI) | p-value |
| Abbreviations: N = number of subjects, n = number of subjects with event; CI = confidence interval, CV = cardiovascular; MI = myocardial infarction | ||||
| Ischemic strokeTime to first occurrence | 384 (6.2%) | 518 (8.4%) | 0.74 (0.65;0.84) | <0.0001Statistically significant |
| Secondary Endpoints: | ||||
| All strokes (ischemic or hemorrhagic) , Ischemic stroke component data are available as primary endpoint. | 404 (6.6%) | 545 (8.8%) | 0.74 (0.65;0.84) | <0.0001 |
| Hemorrhagic stroke | 21 (0.3%) | 28 (0.5%) | 0.75 (0.43;1.33) | |
| Composite of CV death, MI, or stroke , Stroke component data are available as first secondary endpoint. | 568 (9.2%) | 685 (11.1%) | 0.83 (0.74;0.92) | 0.0008 |
| CV death | 148 (2.4%) | 163 (2.6%) | 0.91 (0.73;1.14) | |
| MI | 72 (1.2%) | 60 (1.0%) | 1.21 (0.86;1.70) | |
| Composite of all-cause mortality, MI, or stroke | 649 (10.5%) | 757 (12.3%) | 0.86 (0.77;0.95) | 0.003 |
| All-cause mortality | 248 (4.0%) | 253 (4.1%) | 0.98 (0.83;1.17) | |
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
Sunharbo 50 mg tablets are supplied as dark orange, film-coated, oval, biconvex tablets marked 'BAY' on one side and '50' on the other side. Sunharbo tablets are available in the following package sizes:
| NDC 50419-399-01 NDC 50419-399-10 |
16.2 Storage and Handling
Store at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Store in original bottle. Do not remove desiccant.
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Advise patients and/or caregivers to inform their healthcare provider before scheduling any surgery or other invasive procedure because Sunharbo should be withheld at least 24 hours prior to the surgery or procedure [see Dosage and Administration (2.4)].
For patients unable to swallow whole tablets, advise patients and/or caregivers that tablets may be crushed, mixed with water or soft foods and administered by mouth as an oral suspension or administered via a feeding tube [see Dosage and Administration (2.2)].
Advise patients to take a missed dose as soon as possible on the same day. If the missed dose cannot be taken within the same day, the patient should skip the missed dose and resume with the next scheduled dose at the regular time [see Dosage and Administration (2.3)].
Pregnancy
Advise patients who are exposed to Sunharbo during pregnancy to contact Bayer Healthcare Pharmaceuticals Inc.at 1-888-842-2937 [see Use in Specific Populations (8.1)].
Lactation
Advise females not to breastfeed during treatment with Sunharbo and for 5 days after the last dose [see Use in Specific Populations (8.2)].
© 2026, Bayer HealthCare Pharmaceuticals Inc., All rights reserved.
Distributed by
Bayer HealthCare Pharmaceuticals Inc.
Whippany, NJ 07981
